<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649597</url>
  </required_header>
  <id_info>
    <org_study_id>BEHZ-0210</org_study_id>
    <nct_id>NCT00649597</nct_id>
  </id_info>
  <brief_title>Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg</brief_title>
  <official_title>Single-Dose Fasting In Vivo Bioequivalence Study of Benazepril HCl and Hydrochlorothiazide Tablets (20 mg/25 mg; Mylan) to Lotensin HCT® Tablets (20 mg/25 mg; Novartis) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mylan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and&#xD;
      hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets&#xD;
      following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting&#xD;
      conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <primary_completion_date type="Actual">December 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>within 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotensin HCT® Tablets 20 mg/25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg</intervention_name>
    <description>20/25mg, single dose fasting</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotensin HCT® Tablets 20 mg/25 mg</intervention_name>
    <description>20/25mg, single dose fasting</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female.&#xD;
&#xD;
               1. Women of childbearing potential must have negative serum -human chorionic&#xD;
                  gonadotropin (B-HCG) pregnancy tests performed within 14 days prior to the start&#xD;
                  of the study and on the evening prior to each dose administration. If dosing is&#xD;
                  scheduled on Sunday or Monday, serum samples for β-HCG testing may be collected&#xD;
                  and sent for analysis within 48 hours prior to dosing for both study periods. An&#xD;
                  additional serum (beta-HCG) pregnancy test will be performed upon completion of&#xD;
                  the study.&#xD;
&#xD;
               2. Women of childbearing potential must practice abstinence or be using an&#xD;
                  acceptable form of contraception throughout the duration of the study. Acceptable&#xD;
                  forms of contraception include the following:&#xD;
&#xD;
                    1. oral contraceptives initiated at least 3 months prior to the start of the&#xD;
                       study and continued during the study, or&#xD;
&#xD;
                    2. intrauterine device in place for at least 3 months prior to the start of the&#xD;
                       study and remaining in place during the study period, or&#xD;
&#xD;
                    3. barrier methods containing or used in conjunction with a spermicidal agent,&#xD;
                       or&#xD;
&#xD;
                    4. postmenopausal or surgical sterility accompanied with a documented&#xD;
                       postmenopausal course of at least one year (tubal ligation, oophorectomy or&#xD;
                       hysterectomy).&#xD;
&#xD;
               3. During the course of the study, from study screen until study exit - including&#xD;
                  the washout period, women of childbearing potential must use a spermicide&#xD;
                  containing barrier method of contraception in addition to their current&#xD;
                  contraceptive device. This advice should be documented in the informed consent&#xD;
                  form.&#xD;
&#xD;
                  3. Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and all&#xD;
                  subjects within 15% of Ideal Body Weight (IBW), as referenced by the Table of&#xD;
                  &quot;Desirable Weights of Adults&quot; Metropolitan Life Insurance Company, 1999 (See Part&#xD;
                  II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
                  4. All subjects should be judged normal and healthy during a pre-study medical&#xD;
                  evaluation (physical examination, laboratory evaluation, 12-lead ECG, Hepatitis&#xD;
                  B, Hepatitis C and HIV testing, and urine drug screen including amphetamine,&#xD;
                  barbiturates, benzodiazepines, cannabinoid, cocaine, opiate screen,&#xD;
                  phencyclidine, and methadone) performed within 14 days of the initial dose of&#xD;
                  study medication.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  1. Institutionalized subjects will not be used. 2. Social Habits:&#xD;
&#xD;
               1. Use of any tobacco products.&#xD;
&#xD;
               2. Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage&#xD;
                  within the 48 hours prior to the initial dose of study medication.&#xD;
&#xD;
               3. Ingestion of any vitamins or herbal products within the 48 hours prior to the&#xD;
                  initial dose of the study medication.&#xD;
&#xD;
               4. Any recent, significant change in dietary or exercise habits.&#xD;
&#xD;
               5. A positive test for any drug included in the urine drug screen. 3. Medications:&#xD;
&#xD;
               1. Use of any medication within the 14 days prior to the initial dose of study&#xD;
                  medication, excluding hormonal contraceptives or hormonal replacement therapy&#xD;
                  initiated at least 3 months prior to study medication dosing.&#xD;
&#xD;
               2. Use of any medication known to alter hepatic enzyme activity within 36 days prior&#xD;
                  to the initial dose of study medication, excluding hormonal contraceptives or&#xD;
                  hormonal replacement therapy initiated at least 3 months prior to study&#xD;
                  medication dosing.&#xD;
&#xD;
                  4. Diseases:&#xD;
&#xD;
               1. History of any significant cardiovascular, hepatic, renal, pulmonary,&#xD;
                  hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic&#xD;
                  disease.&#xD;
&#xD;
               2. History of angioedema.&#xD;
&#xD;
               3. History of drug and/or alcohol abuse.&#xD;
&#xD;
               4. Acute illness at the time of either the pre-study medical evaluation or dosing.&#xD;
&#xD;
               5. Positive test for HIV, Hepatitis B, or Hepatitis C. 5. Abnormal and clinically&#xD;
                  significant laboratory test results:&#xD;
&#xD;
               1. Clinically significant deviation from the Guide to Clinically Relevant&#xD;
                  Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).&#xD;
&#xD;
               2. Abnormal and clinically relevant ECG tracing. 6. Donation or loss of a&#xD;
                  significant volume of blood or plasma (&gt; 450 mL) within 28 days prior to the&#xD;
                  initial dose of study medication.&#xD;
&#xD;
                  7. Subjects who have received an investigational drug within 30 days prior to the&#xD;
                  initial dose of study medication.&#xD;
&#xD;
                  8. Allergy or hypersensitivity to benazepril HCl or hydrochlorothiazide or any&#xD;
                  other related products.&#xD;
&#xD;
                  9. History of difficulties in swallowing, or any gastrointestinal disease which&#xD;
                  could affect the drug absorption.&#xD;
&#xD;
                  10. Consumption of grapefruit or grapefruit containing products within 7 days of&#xD;
                  drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James d Carlson, Pharm. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mpibiostudies.com</url>
    <description>Mylan Pharmaceuticals Inc. - Clinical Trial Results</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>March 30, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2008</last_update_submitted>
  <last_update_submitted_qc>March 31, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Will Sullvan, Global Head of Product Risk and Safety Management</name_title>
    <organization>Mylan Inc.</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Benazepril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

